Fixed artesunate–amodiaquine combined pre-formulation study for the treatment of malaria

A New Handheld Device for the Detection of Falsified Medicines: Demonstration on Falsified Artemisinin-Based Therapies from the Field

“…The spectra in (C) represent scans from both bilayer tablet and multi-tablet doses.). Note that formulations of artesunate–amodiaquine are shown as separate spectra despite being part of the same combination therapy, as these compounds (artesunate and amodiaquine salt) are unstable together, which necessitates for them to be formulated either as two separate tablets or as separate layers of a bilayer tablet 17,18Figure 2C shows the combined spectra for both bilayer and multi-tablet therapies.…”

Fixed-Dose Artesunate–Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial

“…The ASAQ fixed-dose combination (FDC) tested in this study (artesunate–amodiaquine Winthrop, or ASAQ Winthrop) was codeveloped by DNDi and Sanofi. This formulation was shown to result in better compliance and reduced risk of emergence of P. falciparum resistance when compared with loose-dose combinations and coblisters [21, 22]. We conducted this clinical trial in order to evaluate the efficacy and safety of the ASAQ FDC compared with that of CQ against uncomplicated P. vivax infection.…”

Preliminary pharmaceutical development of antimalarial–antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas

“…AZ aqueous solubility (39 g L −1 at pH 7.4 and 37 °C (Pfizer, 2013)) was not limiting regarding the dose considered (421 mg AZ dihydrate). In contrast, artemisinin derivatives are characterized by their low aqueous solubility: 0.296 g L −1 (Kauss et al, 2010) and 0.161 g L −1 (Gabriëls & Plaizier-Vercammen, 2004) for AS and AM respectively at 37 °C. For dosage forms containing 300 mg of an artemisinin derivative, this solubility was insufficient to meet solubility (ideally sink, i.e.…”